- Reported VYXEOS drug granted breakthrough therapy designation
- Surprising earnings estimates Wednesday reporting $0.22 EPS vs estimates of $0.18 while reporting sales of $749.4 million vs estimates of $731.4 million
- Raising EPS outlook from $1.90–$1.95 to $1.95–$2.00 in guidance this morning and reporting FY16Q1 adjusted EPS of $1.01 vs estimates of $0.90
- Reported Q1 EPS $0.98 vs $0.88 est., sales $115.9 billion vs $113.22 billion est. and positive guidance
- Reported Wednesday FY16Q1 EPS $0.25, in line; sales $763 million vs $759.4 million est.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in